Documente Academic
Documente Profesional
Documente Cultură
depresiei la vârstnici
Cãtãlina TUDOSE*, Sorin PAVELIU**
Rezumat Abstract
INTRODUCERE
MEDICAMENTE ANTIDEPRESIVE
UTILIZATE ÎN PRACTICA PSIHIATRICÃ
PARTICULARITATI FARMACOCINETICE
ALE PACIENTILOR VARSTNICI
Modificarea distributiei
Distributia unui medicament este influentatã de solubilitatea relativã în lipide, de
afinitatea pentru diferite tesuturi ale organismului, de nivelul fluxului sanguin
cãtre acele tesuturi, de gradul de legare de proteinele plasmatice. Volumul de
distributie al antidepresivelor este, de regulã, mare (cantitatea de medicament
din organism raportatã la concentratia medicamentului în sânge), ceea ce
sugereazã cã o micã parte a medicamentului se aflã în plasmã. Cu cât proportia
tesutului adipos creste, cu atât mai mult se va distribui medicamentul în
organism. Timpul de înjumãtãtire este proportional cu volumul de distributie.
Durata de actiune a medicamentelor lipofilice depinde de distributie, de
metabolizare si mai putin de eliminare.
Adesea activitatea citocromului P450 descreste cu vârsta, reactiile din faza a II-
a fiind mai putin influentate.
Antidepresivele triciclice
Efectele cardiovasculare ale ADT fac ca acesti agenti sã fie mai periculosi în
supradozã decât alte antidepresive, deoarece chiar dozele relativ mici pot fi
fatale (Crome, 1986).
Inhibitorii ai monoaminooxidazei
Desi acesti agenti s-au dovedit a fi eficienti la vârstnici, folosirea lor este limitatã
de riscul efectelor adverse cum ar fi insomnia si sedarea diurnã si de
interactiunile cu alte medicamente sau alimente continând mari concentratii de
tiaminã, care pot conduce la crize hipertensive (Teicher si colab., 1988).
Venlafaxine
Alte antidepresive
INTERACÞIUNI MEDICAMENTOASE
Antidepresivele triciclice
Inhibitorii monoaminooxidazei
Bibliografie
1. Abernethy D.R. (1992) Psychotropic drugs and the aging process. In: clinical
geriatric pharmachology. 2nd edn, Williams & Wilkins Baltimore.
2. Altamura A.C. et al. (1989) Clinical activity and tolerability of trazodone,
mianserin and amitriptiline in elderly patients with major depression. Clin
Neuropharmacol, 12(Suppl 1).
3. Altamura A.C., Moro A.R., Percudani M. (1994) Clinical pharmacokinetics of
fluoxetine. Clin Pharmacokinet. Mar; 26(3):201-14 Related Articles, Links.
4. Avery’s Drug Treatment. (1988) Principles and practice of clinical
pharmacology and therapeutics. Editia a III-a. Addis Press Limited, 1138-1206.
5. Baldwin R.C., Simpson S. (1997) Prognosis and outcomes studies in late life
depression. Clin Neurosci, 4: 16-22.
6. Baldwin R.C. et al. (2002) Guidelines on Depression in Older People.
Practising the Evidence. Martin Dunitz ltd.
7. Benfield P., Heel R.C., Lewis S.P. (1986) Fluoxetine. Drugs, 32: 481-508.
8. Bergstrom R.F. et al. (1988) Clinical pharmachology and pharmacokinetics of
fluoxetine. BRJ Psychiatry, 153: Suppl. 3.
9. Blazer D.G. (1997) Depression in the elderly and misconceptions. Psych Clin
North Am 20: 119-19.
10. Borkan G.A. et al. (1983) Age changes in body composition revealed by
computed tomography. J Gerontol, 38: 673-7.
11. Boyer W., Feighner J.P. (2001) Utility of SSRIs in anxious depression. In:
SSRIs in Depression and Anxiety 2nd edn, Wiley.
12. Crome P. (1986) Poisoning due to tricyclic antidepressant overdoses. Med
Toxicol, 1: 261-85.
13. Fontaine R. et al. (1994) A double blind comparation of nefazodone,
imipramine and placebo in major depression. J Clin Psychiatry.
14. Francis J., Martin D., Kapoor V.N. (1990) A prospective study of delirium in
hospitalized elderly. JAMA, 263:1097-101.
15. Fraser R.M., Glass I.B. (1980) Unilateral and bilateral ECT in elderly
patients. Acta Psychiatr Scand, 62: 13-31.
16. Kramer B.A. (1987) Electroconvulsive therapy use in geriatric depression. J
Nerv Ment Dis., 175 233-5.
17. Leucuta Sorin. (1989) Farmacocinetica în terapia medicamentoasã. Ed.
Medicalã.
18. Lippincott’s illustrated reviews: Pharmacology. (1997) 2nd edition.
Lippincott-Raven Publishers.
19. Georgotas et al. (1989) Factors affecting the delay of antidepressant effect
in responders to nortriptiline and phenelzine. Psychiatry Res, 28:1-9.
20. Glassman A.H., Roose S.P. (1994) Risk of antidepressant in elderly.
Gerontology, 40(Suppl 1).
21. Guelfi J.D. et al. (1995) Effectiveness of venlafaxine in patients hospitalized
for major depression and melancholia. J Clin Psychiatry 56:450-8.
22. Guillibert E., Pelicier Y., Archambault J.C. et al. (1989) A double-blind,
multicenter study of paroxetine versus clomipramine in depressed elderly
patients. Acta Psychiatr, 80:132-4.
23. Halikas J.A. (1995) Org 3770 (mirtazapine) versus trazodone: a placebo
controlled trial in depressed elderly patients. Hum Psycho-pharmacol. 10(Suppl
2:125-33.
24. Kaye C.M. et al. (1989) A review of metabolism and pharmacokinetics of
paroxetine in men. Acta Psychiatr Scand Suppl, 80(350).
25. McCue R.E. et al. (1989) Plasma levels of nortriptiline and 10-
hidroxinortriptiline and treatment related electrocardiografic changes in the
elderly depressed. J Psychiatr Rev.
26. Meyers B.S., Alpert S., Gabriele M. et al. (1993) State specificity of DST
abnormalities in geriatric depression. Biol Psychiatry (United States), Jul 1-15,
34(1-2): 108-14.
27. Moret et al. (1985) Biochemical profile of midalcipran (F2207)
Neuropharmachology, 24.
28. Naranjo et al. (1995) Recent advances in geriatric psychopharmachology.
Drus aging, 7: 184-202.
29. Newhouse P.A. (1996) Use of serotonin selective reuptake inhibitors in
geriatric depression. J Clin Psychiatry (United States), 57 Suppl 5 p12-22.
30. NIH Consensus Development Panel on Depression in Late Life. (1992)
Diagnosis and treatment of depression. JAMA.
31. Nyth A., Gottfries C.G. (1990) The clinical efficacy of citalopramin treatment
of emotional disturbances in dementia disorders: a Nordic multicenter study. Br
J Psychiatry, 157: 894-901.
32. Nyth A.L., Syversen S., Eriksson S. et al. (1992) A controlled multicenter
clinical study of citalopram and placebo in elderly depressed patients with and
without concomitant dementia. Acta Psychiatr Scand, 86: 138-45.
33. Pages L.J. et al. (1988) Safety and pharmacokinetics of sertraline. J Clin
Pharmacol, 28:908-59.
34. Preskorn S.H. et al. (1990) Serious adverse effects of combining fluoxetine
and tricyclic antidepressants. Am J Psychiatry, 147:532.
35. Reid F., Henry J.A. (1990) Lofepramine overdosage. Pharmacopsychiatry
23 (Suppl 1): 23-7.
36. Ray W.A. (1992) Psychotropic drugs and injuries among the elderly: a
review. J Clin Psychopharmacol (United States), Dec, 12(6): 386-96.
37. Rikels K., Weise C.C., Zal H.M. (1982) Lofepramine and imipramine in
unipolar depressed outpatients. Acta Psychiatr Scand, 66: 109-20.
38. Riedel W.J., Van Praag H.M. (1995) Avoiding and managing anticholinergic
effects of antidepressants. CNS Drugs. 3: 245-59.
39. Rizos A.L., Sargenti C.J., Jeste D.V. (1988) Psychotropic drug interactions in
the patient with late-onset depression or psychosis, part 2. Psychiatr Clin North
Am, 11: 253-77.
40. Reidenberg M. (1982) Drugs in the elderly. Med Clin North Am, 66: 1073-8.
41. Reidenberg M. (1987) Drug therapy in the elderly: the problem from the
point of view of a clinical pharmacologist. Clin Pharmacol Ther (United States),
Dec, 42(6): 677-80.
42. Reynolds C.F., Frank E., Perel J.M. (1992) Combined pharmacotherapy and
psychotherapy in acute and continuation treatment of elderly patients with
recurrent major depression: a preliminary report. Am J Psychiatry, 149: 1687-92.
43. Reynolds C.F. (1994) Treatment of depression in late life. Am J Med, 97
(Suppl 6A): 39-46.
44. Reynolds C.F., Frank E., Perel J.M. (1995) Maintenance therapies for late
life recurrent major depression: research and review circa 1995. Int
Psychogeriatr, 7 (Suppl): 27-39.
45. Roose et al. (1987) Tricyclic antidepressants in depressed patients with
cardiac conduction disease. Ach Gen Psychiatry.
46. Rotschild A.J. (1996) The diagnosis and treatment of late-life depression. J
Gen Psychiatry, 57(Suppl 5): 5-11.
47. Sloley B.D., Urichuk L.J., Morley P., Durkin J., Shan J.J., Pang P.K., Coutts
R.T. (2000) Identification of kaempferol as a monoamine oxidase inhibitor and
potential Neuroprotectant in extracts of Ginkgo biloba leaves. J Pharm
Pharmacol, Apr; 52(4): 451-9 Related Articles, Links.
48. Stoudemire A., Moran M.G., Fogel B.S. (1995) Psychopharmacology in the
medically ill patient. In: The American Psychiatric Press Textbook of
Psychopharmacology pp783-801. American Psychiatric Press: Washington.
49. StroescuV. (1998) Bazele farmacologice ale practicii medicale. ed. VI. Ed.
Medicalã, 1042-1059.
50. Teicher M.H. (1988) Severe daytime somnolence in patients treated with an
MAOI. Am J Psychiatry, 145: 1552-6.
51. Wernicke J.F. (1985) The side effect profile and safety of fluoxetine. J Clin
Psychiatry, 46: 59-67.
52. Tumer N., Scarpace P.J., Lowenthal D.T. (1992) Geriatric pharmachology:
basic and clinic considerations. Ann Rev Pharmacol Toxicol, 32: 271-302.
53.Verhey F.R.J., Honig A. (1997) Depression in the elderly. In: Depression:
Neurobiological, Psychopathological and therapeutic advances. John Wiley:
Chichester.
54. Wood P. (2002) Psychopharmacology in elderly patients 286-315. In
Psychiatry in the Elderly, 3rd edn, Oxford Medical Publications.
55. (http://acnp.org/G4/GN401000140/137_1.htm)